布地奈德治疗哮喘的疗效怎么样？

(Budesonide, Budenofalk) is a non-halogenated glucocorticoid that has a strong local anti-inflammatory effect and is one of the important drugs for the treatment of allergic asthma. Budesonide (Budesonide, Budenofalk) has a long acting time and has no systemic adrenocortical hormone effect. It is more suitable for topical administration. It is a first-line drug for the treatment of asthma by aerosol inhalation and the treatment of allergic reactions by spraying into the nasal cavity. Clinical studies have found that the systemic effects of Budesonide (Budenofalk), such as weight loss, lymphoid tissue and adrenal cortex atrophy, are weaker than or equivalent to other glucocorticoids. After systematic evaluation through six different experimental tests, Budesonide (Budenofalk) has no mutagenic or carcinogenic effects.

Are Budesonide (Budenofalk) effective? Clinical trials have shown that Budesonide (Budenofalk) has good efficacy and high safety when used in bronchial asthma. The trial selected 85 patients with bronchial asthma who received treatment and divided them into an experimental group of 43 patients and a control group of 42 patients using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with Budesonide (Budenofalk). After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results: The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant. No patients in the two groups experienced serious adverse reactions. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant.

From the above information, we can know that the efficacy of (Budesonide, Budenofalk) is very significant. Patients can choose with confidence.